Asthma and COPD Drugs Market Overview:
The Global Asthma and COPD Drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Asthma is a chronic respiratory disease blocking the airways of lung because of inflammation, mucus production, tighten of muscles. Chronic Obstructive Pulmonary Disease(COPD) is caused by obstruction in the airways causing difficulty in breathing, with the primary cause as tobacco smoking.
Symptoms of Asthma and COPD
This report covers information on various types of medication class to treat asthma and COPD in compliance with the European Medical Association (EMA), the U.S. Food and Drugs Administration (FDA), Conformité Européene (CE) and other regulatory authorities. Moreover, this study on the global Asthma and COPD Drugs also focuses on the treatment of the disease which is available in the market.
The Global Asthma and COPD Drugs market is segmented based on disease, medication class and geography. Based on disease, the market is categorized into asthma and COPD. Based on medication class, the market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Based on geography, the market is categorized into North America, Europe, Asia-Pacific, and LAMEA. North America holding major share of the market.
Asthma and COPD Drugs Market Segmentation
The use of drugs has emerged as an effective solution for the treatment of COPD and asthma, which largely contributes to the growth of this market. The market is driven by the growing patient COPD and asthmatic population, as well as FDA approvals for the novel products and its wide acceptance among the patient population. Increasing government initiatives to control COPD and asthma further fuel the growth for this market.
The Asthma and COPD Drug market consists of medication class based on the severity of the disease. Short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids(ICS), leukotriene antagonists (LTA), combination products, anticholinergics and others are the medication class which are used in the treatment of COPD and asthma.
The disease segment consists of the global prevalence of asthma and COPD for market sizing and forecasting the global sales of the Asthma and COPD Drugs. Asthma contributed the highest share, approximately 66.1%, to the world Asthma and COPD Drugs market with the expected to grow at a highest CAGR of 1.3% by 2022.
The growth of the North American and European market is driven by the increasing COPD and asthma patient population and rising number of smokers. North American Asthma and COPD Drugs market is likely to register a CAGR of 3.2% over the analysis period, which would create potential opportunities for new market players to grow.
Top impacting factors
Increase in prevalence of COPD and asthma patients; increase in world ageing population, technological advancement in the treatment of asthma and COPD, increase in pipeline products growth in initiatives implemented by the government and non-government associations for rise in health awareness are the major factors that drive the growth of the Asthma and COPD Drug.
However, stringent government regulatory requirement for the approval of asthma and COPD drugs, the asthma and COPD drugs showing side effects, patent expiry of the drugs restrict the market growth. Furthermore, developing countries, such as China and India, provide huge growth opportunities along with introduction of generic drugs to this market.
The leading market players in the Asthma and COPD Drug focus to expand their business operations in the emerging countries. The companies operating in the market have consistently introduced innovative solutions to enhance their product portfolio. Product approval and clinical trial are observed as the two prominent growth strategies adopted by the key market players. The major players profiled in this report include GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries (Israel), Vectura Group (U.K), Pfizer (U.S).
Other players in the value chain include Mylan, Aerovance Inc. Alkermes Inc. Almirall SA. Genentech Inc. Sepracor, Inc. Skyepharma plc.
Asthma and COPD Drugs Market Key benefits
- The study provides an in-depth analysis of the asthma and COPD drug market with current trends and future estimations to elucidate the imminent investment pockets in the market.
- The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
- Extensive analysis of the asthma and COPD drug market, by medication class, helps in the treatment of asthma and COPD diseases.
- Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
- Key market players within the asthma and COPD drug market are profiled in this report and their strategies are analyzed thoroughly, which predicts the competitive outlook of global asthma and COPD drug market.
ASTHMA AND COPD DRUGS MARKET KEY SEGMENTS
By Medication Class
- Combination Products
- Relvar/Breo Ellipta
- Leukotriene Antagonists (LTA)
- Inhaled Corticosteroids (ICS)
- Short Acting Beta Agonists(SABA)
- Long Acting Beta Agonists (LABA)
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Middle East